— Sarepta Therapeutics, Inc. (NASDAQ: SRPT) reported a loss of $1.57 per share in the fourth quarter of 2019, vs $1.86 per share loss expected.
— Q4 revenue rose 19% to $100.1 million, vs. $98.8 million expected. Results were helped by an increase in demand for EXONDYS 51 in the U.S.
— Appointed biotech executive John C. Martin to Board of Directors. He is a former Gilead CEO.
— SRPT shares ended Wednesday’s regular trading session down 1.14%.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Infographic: How Alaska Air Group (ALK) performed in Q1 2024
Alaska Air Group (NYSE: ALK) reported its first quarter 2024 earnings results today. Total operating revenue increased 2% year-over-year to $2.23 billion. Net loss amounted to $132 million, or $1.05 per
KMI Earnings: Kinder Morgan Q1 2024 adjusted profit increases; revenue drops
Kinder Morgan, Inc. (NYSE: KMI) reported higher adjusted earnings for the first quarter of 2024 despite a decrease in revenues. The energy infrastructure company also issued guidance for the full
What to expect when Altria (MO) reports first quarter 2024 earnings results
Shares of Altria Group, Inc. (NYSE: MO) stayed green on Wednesday. The stock has dropped 8% over the past one month. The tobacco giant is scheduled to report its first
